MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

Molecular Oncology

Volumn 7, Issue 1, 2013, Pages 112-120

  Huang, Ming Hung ^a   Lee, Jih Hsiang ^a,b   Chang, Ya Ju ^c   Tsai, Hsin Hui ^b   Lin, Yu Lin ^b   Lin, Anya Maan Yuh ^c   Yang, James Chih Hsin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

EGF receptor; Gefitinib; Kinase and phosphatase inhibitors; Lung cancer; NRAS; Reversal of drug resistance

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CASPASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; K RAS PROTEIN; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SELUMETINIB; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; EXON; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84872491067     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.09.002     Document Type: Article

References (34)

1. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20932-20937.
2. Chang T.H., Tsai M.F., Su K.Y., Wu S.G., Huang C.P., Yu S.L., Yu Y.L., Lan C.C., Yang C.H., Lin S.B., et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Respir. Crit. Care Med. 2011, 183:1071-1079.
3. Chen H., Zhu G., Li Y., Padia R.N., Dong Z., Pan Z.K., Liu K., Huang S. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res. 2009, 69:9228-9235.
4. Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K., Somwar R., Wang L., Amato K.R., Arcila M., Sos M.L., et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl Med. 2011, 3:90ra59.
5. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363:1734-1739.
6. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
7. Donev I.S., Wang W., Yamada T., Li Q., Takeuchi S., Matsumoto K., Yamori T., Nishioka Y., Sone S., Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin. Cancer Res. 2011, 17:2260-2269.
8. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 2011, 121:4311-4321.
9. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14:2895-2899.
10. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
11. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
12. Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11:909-920.
13. Guo A., Villen J., Kornhauser J., Lee K.A., Stokes M.P., Rikova K., Possemato A., Nardone J., Innocenti G., Wetzel R., et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:692-697.
14. Hainsworth J.D., Cebotaru C.L., Kanarev V., Ciuleanu T.E., Damyanov D., Stella P., Ganchev H., Pover G., Morris C., Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J. Thorac. Oncol. 2010, 5:1630-1636.
15. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., Suehisa H., Ouchida M., Aoe K., Aoe M., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006, 66:7854-7858.
16. Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C.H., Franke F.A., Grinsted L., Smith P.D., Zazulina V., et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2012, 30:7503.
17. Li C., Fang R., Sun Y., Han X., Li F., Gao B., Iafrate A.J., Liu X.Y., Pao W., Chen H., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011, 6:e28204.
18. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., Zhou C., Su W.C., Wang M., Sun Y., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012, 13:528-538.
19. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
20. O'Neil B.H., Goff L.W., Kauh J.S., Strosberg J.R., Bekaii-Saab T.S., Lee R.M., Kazi A., Moore D.T., Learoyd M., Lush R.M., et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2011, 29:2350-2356.
21. Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.L., Pan Y., Wang L., de Stanchina E., Shien K., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2127-E2133.
22. Ono M., Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 2006, 12:7242-7251.
23. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
24. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., Zakowski M.F., Heelan R.T., Kris M.G., Varmus H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2:e17.
25. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
26. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl Med. 2011, 3:75ra26.
27. Sos M.L., Rode H.B., Heynck S., Peifer M., Fischer F., Kluter S., Pawar V.G., Reuter C., Heuckmann J.M., Weiss J., et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010, 70:868-874.
28. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., Ho B.C., Chang G.C., Shih J.Y., Yu S.L., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:433-440.
29. Tang Z., Du R., Jiang S., Wu C., Barkauskas D.S., Richey J., Molter J., Lam M., Flask C., Gerson S., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer 2008, 99:911-922.
30. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
31. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
32. Wakelee H.A., Gettinger S.N., Engelman J.A., Janne P.A., West H.J., Subramaniam D.S., Leach J.W., Wax M.B., Yaron Y., Lara P. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2010, 28(suppl). abstr 3017.
33. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.
34. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.